Topic Hub
34 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 34 of 34 clinical reviews.
Bremelanotide (PT-141, Vyleesi) has no FDA-approved adolescent indication. Learn why off-label use in patients aged 12 to 17 demands rigorous clinical monitoring, what parameters to track, and what the evidence does and does not support.
Read clinical reviewBremelanotide (Vyleesi) has no FDA approval, clinical trial data, or safety profile established for adolescents aged 12, 17. Here is what clinicians and parents need to know.
Read clinical reviewComplete dosing guide for PT-141 (bremelanotide/Vyleesi) in adults aged 30, 49, including FDA-approved dose, injection technique, timing, side effects, and clinical trial data from RECONNECT.
Read clinical reviewEvidence-based review of bremelanotide (Vyleesi) drug-drug interactions, including contraindicated combinations, dose adjustments, and clinical monitoring parameters for prescribers and patients.
Read clinical reviewHow to dose PT-141 (bremelanotide) in adults aged 50-64. Covers FDA-approved 1.75 mg subcutaneous dose, cardiovascular screening, polypharmacy checks, and age-specific clinical considerations.
Read clinical reviewEvidence-based guide to bremelanotide (Vyleesi) dosing adjustments in patients with hepatic impairment, including pharmacokinetic data, clinical recommendations, and monitoring protocols.
Read clinical reviewEvidence-based guide to bremelanotide (Vyleesi) dosing in patients with renal impairment, covering pharmacokinetics, FDA label recommendations, eGFR thresholds, and clinical monitoring.
Read clinical reviewEvidence-based guide to food and supplement interactions with PT-141 (bremelanotide), including timing with meals, alcohol, herbal supplements, and medications that affect efficacy or safety.
Read clinical reviewA clinical review of bremelanotide (PT-141/Vyleesi) pipeline developments, next-generation melanocortin receptor agonists, oral and intranasal formulations under investigation, and what the evolving research means for HSDD and sexual medicine.
Read clinical reviewEvidence-based monitoring guide for PT-141 (bremelanotide) use in adults 65 and older, covering blood pressure tracking, renal adjustments, fall risk, drug interactions, and deprescribing.
Read clinical reviewEvidence-based guide to bremelanotide (Vyleesi / PT-141) dosing in adults aged 65 and older, covering pharmacokinetics, renal adjustments, blood pressure risks, drug interactions, and clinical monitoring.
Read clinical reviewEvidence-based guide to bremelanotide (Vyleesi) use in special populations including organ transplant recipients, people living with HIV, cancer survivors, and patients with chronic kidney disease. Covers safety, drug interactions, and clinical considerations.
Read clinical reviewA clinical overview of bremelanotide (PT-141 / Vyleesi) manufacturing origins, supply chain events, FDA regulatory milestones, and shortage history from development through 2026.
Read clinical reviewClinical guidance on what to do if you miss or delay a dose of PT-141 (bremelanotide), including timing windows, efficacy considerations, and when to contact your provider.
Read clinical reviewEvidence-based monitoring guide for bremelanotide (Vyleesi/PT-141) in adults aged 30-49, covering blood pressure tracking, nausea management, skin checks, and cardiovascular safety.
Read clinical reviewA physician-reviewed guide to monitoring bremelanotide (PT-141) in adults aged 50, 64, covering cardiovascular safety, blood pressure checks, polypharmacy interactions, and perimenopause or andropause considerations.
Read clinical reviewEvidence-based monitoring guide for bremelanotide (Vyleesi/PT-141) in young adults aged 18 to 29, covering blood pressure checks, melanocyte screening, fertility considerations, and follow-up intervals.
Read clinical reviewEvidence-based monitoring schedule for PT-141 (bremelanotide/Vyleesi), including baseline labs, blood pressure checks, and follow-up exams required before and during therapy for HSDD.
Read clinical reviewA clinical review of bremelanotide (PT-141) off-label applications beyond HSDD, including erectile dysfunction, anorgasmia, and emerging melanocortin-pathway indications, graded by available evidence.
Read clinical reviewWhen will generic bremelanotide (Vyleesi) become available? A detailed analysis of PT-141 patent expirations, Hatch-Waxman exclusivity, and projected generic entry dates.
Read clinical reviewPT-141 (bremelanotide) is not approved for pediatric use under age 12. Learn why, what the FDA label says, and how clinicians should respond to off-label requests.
Read clinical reviewBremelanotide (PT-141, Vyleesi) is FDA-approved only for premenopausal HSDD. No pediatric data, no pediatric indication, and no safe monitoring protocol exists for children under 12.
Read clinical reviewA clinical review of PT-141 (bremelanotide) safety in pediatric patients under 12, covering FDA labeling, melanocortin receptor pharmacology, absence of pediatric trial data, and why this drug is contraindicated in children.
Read clinical reviewHow genetic variants in melanocortin-4 receptor (MC4R) and CYP enzymes shape individual response to bremelanotide (Vyleesi), including pharmacokinetic variability, dosing implications, and emerging pharmacogenomic research.
Read clinical reviewA clinical breakdown of bremelanotide (Vyleesi/PT-141) pharmacokinetics including absorption after subcutaneous injection, distribution, hepatic metabolism, renal excretion, and factors affecting drug levels.
Read clinical reviewA clinician-grade review of bremelanotide (Vyleesi/PT-141) real-world evidence from registries, post-marketing surveillance, and observational data, including efficacy rates, safety signals, and patient-reported outcomes.
Read clinical reviewA clinical review of bremelanotide (Vyleesi / PT-141) regulatory approvals, rejections, and pending status across the United States, European Union, Canada, and United Kingdom.
Read clinical reviewA physician-reviewed guide to bremelanotide (PT-141) safety, dosing, side effects, and clinical considerations for young adults aged 18, 29, including fertility, contraception, and cardiovascular risk.
Read clinical reviewA clinical review of bremelanotide (Vyleesi / PT-141) safety signals, FDA regulatory history, cardiovascular warnings, and post-market surveillance data for HSDD treatment.
Read clinical reviewLearn the correct subcutaneous self-injection technique for PT-141 (bremelanotide/Vyleesi), including site selection, dose preparation, timing, and managing common side effects like nausea and flushing.
Read clinical reviewEvidence-based guide to storing bremelanotide (Vyleesi/PT-141) correctly, including temperature requirements, reconstitution stability, shelf life data, and what happens when the cold chain breaks.
Read clinical reviewEvidence-based guide to PT-141 (bremelanotide) dosing for young adults aged 18 to 29, covering FDA-approved protocols, off-label considerations, safety monitoring, and fertility planning.
Read clinical reviewA clinical history of bremelanotide (PT-141), from its origins as a synthetic melanocortin peptide to FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Read clinical reviewEvidence-based guide to switching between bremelanotide (PT-141/Vyleesi) and other sexual desire or erectile dysfunction medications, including flibanserin, PDE5 inhibitors, and testosterone therapy.
Read clinical review